Therapies directed at HER2 in breast cancer establish a successful paradigm that suggests other molecular-targeted treatments may prove useful in this disease. Though their functions overlap, laboratory data suggest that HER2/HER3 heterodimers predominantly activate the Akt/PI3-kinase cell survival pathway, while HER1/HER2 heterodimers mainly activate cell proliferation by the ERK1,2 MAP-kinase pathway. Trastuzumab, a humanized monoclonal antibody against HER2, is highly efficacious in breast cancer. Our preliminary data in human breast cancer biopsies obtained from a neoadjuvant trastuzumab clinical study indicates that the main mechanism of action of trastuzumab is by affecting Akt/PI3-kinase survival pathways, thereby inducing apoptosis, without significant changes in cell proliferation (Ki67 and p27). We and others have laboratory data suggesting that therapies designed to block both HER1/HER2 and HER2/HER3 pathways might be superior to either strategy alone in human breast cancers. We hypothesize that a small molecule like GW572016 which inhibits both Akt/PI3-kinase cell survival and ERK 1,2 MAP-kinase cell proliferation pathways by blocking HER1 and HER2. thereby inducing apoptosis and decreasing cell proliferation as dual mechanisms of action, will be an effective single agent in HER1/HER2 over-expressing breast cancer, and may be superior to therapies that affect either pathway alone (1). To test this hypothesis, we propose to perform a neoadjuvant clinical trial with GW572016, in which serial cancer tissue samples will be obtained for molecular studies in relation to tumor response. The following specific aims are proposed: (1) To demonstrate the clinical efficacy of GW572016 in patients with HER1/HER2-overexpressing locally advanced breast cancer, with and without gross concomitant metastatic disease, by assessing in a neoadjuvant trial the clinical response rate and toxicity of GW572016 in treatment-naive patients, and to obtain serial specimens from primary breast cancers at different time-points. (2) To determine if GW572016 inhibits HER1 and HER2 signaling in vivo in these sequential core biopsies by assessing cell survival pathways (apoptosis by cleaved caspase 3, and phosphorylated Akt), cell cycle arrest (ERK1,2 MAP-kinase, Ki67, and p27), and down-regulation of total and phosphorylated HER1 and HER2. (3) To identify predictive markers for sensitivity and resistance to GW572016 by gene expression array analysis of pretreatment samples. With normal vasculature and surrounding stromal milieu, these serial samples of human breast cancer will provide important information on the in vivo mechanisms of action of GW572016, a promising novel small molecule with dual specificity against HER1 and HER2, together with molecular signatures that may predict response and resistance to this agent.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA112305-02
Application #
7082220
Study Section
Clinical Oncology Study Section (CONC)
Program Officer
Xie, Heng
Project Start
2005-06-16
Project End
2010-04-30
Budget Start
2006-06-01
Budget End
2007-04-30
Support Year
2
Fiscal Year
2006
Total Cost
$259,769
Indirect Cost
Name
Baylor College of Medicine
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Dobrolecki, Lacey E; Airhart, Susie D; Alferez, Denis G et al. (2016) Patient-derived xenograft (PDX) models in basic and translational breast cancer research. Cancer Metastasis Rev 35:547-573
Park, Jun Hyoung; Vithayathil, Sajna; Kumar, Santosh et al. (2016) Fatty Acid Oxidation-Driven Src Links Mitochondrial Energy Reprogramming and Oncogenic Properties in Triple-Negative Breast Cancer. Cell Rep 14:2154-2165
Patel, Tejal A; Dave, Bhuvanesh; Rodriguez, Angel A et al. (2014) Dual HER2 blockade: preclinical and clinical data. Breast Cancer Res 16:419
Landis, Melissa D; Lehmann, Brian D; Pietenpol, Jennifer A et al. (2013) Patient-derived breast tumor xenografts facilitating personalized cancer therapy. Breast Cancer Res 15:201
Zhang, Xiaomei; Claerhout, Sofie; Prat, Aleix et al. (2013) A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res 73:4885-97
Dave, Bhuvanesh; Landis, Melissa D; Tweardy, David J et al. (2012) Selective small molecule Stat3 inhibitor reduces breast cancer tumor-initiating cells and improves recurrence free survival in a human-xenograft model. PLoS One 7:e30207
Dave, Bhuvanesh; Migliaccio, Ilenia; Gutierrez, M Carolina et al. (2011) Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol 29:166-73
Atkinson, Rachel L; Zhang, Mei; Diagaradjane, Parmeswaran et al. (2010) Thermal enhancement with optically activated gold nanoshells sensitizes breast cancer stem cells to radiation therapy. Sci Transl Med 2:55ra79
Yang, Wei Tse; Lewis, Michael T; Hess, Kenneth et al. (2010) Decreased TGFbeta signaling and increased COX2 expression in high risk women with increased mammographic breast density. Breast Cancer Res Treat 119:305-14
Creighton, Chad J; Chang, Jenny C; Rosen, Jeffrey M (2010) Epithelial-mesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in breast cancer. J Mammary Gland Biol Neoplasia 15:253-60

Showing the most recent 10 out of 13 publications